Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 263-093-9 | CAS number: 61789-86-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
Based on the available animal that all show positive results and the human data that demonstrate positive results at and above 10%w/w concentration it is considered that the low TBN substance is classified as a skin sensitiser. These results also show that the high TBN substance is not a skin sensitizer.
Classification and Labeling is proposed and explained for Sulfonic acids, petroleum, calcium salts using data from skin sensitization studies on natural and synthetic calcium sulfonates. For Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) classification and labeling, EU Classification, Labeling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008 applies.
In the lubricant additive industry, calcium sulfonate is a common name for natural and synthetic long-chain alkylbenzenesulfonic acids, calcium salts. Calcium sulfonates, which have surfactant properties, are used as detergents in a broad variety of lubricant applications. In some cases, excess calcium carbonate is added to calcium sulfonates to add acid buffering capacity (commonly known as “overbasing”). Calcium sulfonates with a large excess of calcium carbonate are referred to as high overbased or high total base number (TBN) calcium sulfonates, whereas calcium sulfonates with small amounts of added calcium carbonate are called low overbased or low TBN calcium sulfonates. Animal studies show that calcium sulfonates with a TBN greater than 300 are not skin sensitizers while the results in animals at a TBN of 300 exhibit a mixed skin sensitization response. However, human repeat insult patch tests clearly show that high TBN overbased calcium sulfonates (TBN ≥ 300) are not sensitizers and that low TBN calcium sulfonates do not cause sensitization in a substantial number of persons at concentrations of 10% or lower within the definition of sensitization under EU Regulation (EC) No. 1272/2008.
Sensitization:
Low TBN Calcium Sulfonates
In a key study the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 13) was evaluated in the local lymph node assay (LLNA) (Lees, 1996). Groups of male mice (4/group) were dose with approximately 25 µL of 0.1, 1, 10 or 30% concentrations of the test material in DMF on the dorsal surface of each ear for three consecutive days. The animals were then injected with 3H-methylthymidine, and the auricular lymph nodes where then collected and prepared for scintillation counting. A three-fold or greater increase in isotope incorporation was observed at all test concentrations. Although investigators have reported that LLNA over predicts the sensitisation potential of surfactants (Basketter & Kimber, 2011; Ball et al., 2011), the positive response in this study is supportive of the sensitisation response for low TBN calcium sulfonates noted in other sensitisation studies.
In another key study the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 13) was evaluated in guinea pigs (Bonnette, 1993b;Table28). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 50% concentration of the test substance. After approximately one week the animals were rechallenged with a 25% concentration of the test substance. Following the first rechallenge, the animals then were rechallenged with a 10% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 50%, 25%, and 10% were 9/10, 10/10, and 9/10, respectively, and the mean 24/48 hour Draize scores were 1.9/2.1, 1.6/2.0, and 1.5/1.5, respectively. The mean 24/48 hour Draize scores for the naïve controls at 50%, 25%, and 10% were 0.2/0.2, 0.7/0.6, and 0.5/0.5, respectively. Based on these results the test substance was determined to be a sensitiser.
Table28. Dermal Sensitisation Study (Modified Buehler Design) in Guinea Pigs with a 100% Low TBN Calcium Sulfonate (Benzenesulfonic Acid, 4-(Mono-C15-36 Branched Alkyl Derivs., C24 Rich) and Benzenesulfonic Aacid, 4-Octadecyl, Calcium Salts; EC 939-141-6; TBN = 13) Induction: Challenge Results (Bonnette, 1993b)
Group
Concentration
Mean Draize Score
# Positive
Conclusion
24 hours
48 hours
Test
50%
1.9
2.1
9/10
Sensitiser
Control
50%
0.2
0.2
Test
25%
1.6
2.0
10/10
Sensitiser
Control
25%
0.7
0.6
Test
10%
1.5
1.5
9/10
Sensitiser
Control
10%
0.5
0.5
Control = Topical application of test article to naïve animals to account for primary irritation reactions
In another key study the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 13) was evaluated in guinea pigs (Shults, 1993). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 25% concentration of the test substance. After approximately one week the animals were rechallenged with a 10% concentration of the test substance. Following the first rechallenge, the animals then were rechallenged with a 10% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 25%, 10% rechallenge, and 10% second rechallenge were 10/10, 9/10, and 7/10, respectively, and the mean 24/48 hour Draize scores were 1.4/1.15, 0.8/0.95, and 0.8/0.85, respectively. The mean 24/48 hour Draize scores for the naïve controls at 25%, 10% rechallenge, and 10% second rechallenge were 0.8/0.06, 0.55/0.6, and 0.3/0.65, respectively. Based on these results the test substance was determined to be a sensitiser.
In another key study the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 13) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1993a;Table 29).A panel of 53 subjects was identified for this test. In the induction phase the undiluted (100% concentration) test substance was administered directly to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 44 subjects that completed the induction phase was topically challenged with the undiluted (100% concentration) test substance. Positive responses (scores ≥ 1) were observed in 9/44 and 6/44 at the 24 and 72 hour readings, respectively. Rechallenge of the six subjects suspective of exhibiting allergic reactions confirmed allergic contact dermatitis in four (4/44 or 9%). Based on these results the test substance was determined to be a sensitiser.
In another key study the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 13) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994c;Table 29). A panel of 55 subjects was identified for this test. In the induction phase a 20% concentration of the test substance in mineral oil was administered directly to the skin and covered with a semi-occlusive patch threetimes per week for a total of nine applications. Following a two week rest period, each of the 45 subjects thatcompleted the induction phase was topically challenged with a 20% concentration of the test substance in mineral oil. Positive responses (scores ≥ 1) were observed in 16/45 and 16/45 at the 24 and 72 hour readings (or 48 or 96 hour make up readings), respectively. Approximately 31 % (14/45) of the test population exhibited skin reactivity patterns that were suggestive or indicative of low to moderate grade, induced allergic contact dermatitis. Based on these results the test substance was determined to be a sensitiser.
Table29. Human Repeat Insult Patch Tests (HRIPT) with a Low TBN Calcium Sulfonate (Benzenesulfonic Acid, 4-(Mono-C15-36 Branched Alkyl Derivs., C24 Rich) and Benzenesulfonic Aacid, 4-Octadecyl, Calcium Salts; EC 939-141-6; TBN = 13): Challenge Results
Test Phase
Concentration
# Positive Responses
Conclusion
Study
24 hours
72 hours
Induction
100%
Sensitiser
Shanahan & Erianne, 1993a
Challenge
100%
9/44
6/44
Induction
20%
Sensitiser
Shanahan & Erianne, 1994c
Challenge
20%
16/45*
16/45*
*48 or 96 hour make-up readings were required for some subjects
Low TBN Specific Concentration Limit (SCL)
The weight-of-evidence of all the animal and human studies demonstrates that low TBN calcium sulfonates are skin sensitisers. However, well-conducted, reliable, controlled HRIPT studies show that these substances do not cause sensitisation in a substantial number of subjects at 10% and lower.
In another key study the dermal sensitisation of an analogue of this low TBN substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 30) was evaluated in a human repeat insult patch test (Alworth, Schwartz, & Erianne, 1995c;Table30). Five panels consisting of a total of 166 subjects were identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 142 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 8/142 (5.6%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to cause a low incidence of sensitisation characterized by mild to moderate reactions in all but one subject.
In another key study the dermal sensitisation of an analogue of this low TBN substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 30) was evaluated in a human repeat insult patch test (Eisenberg,1994c;Table30). A panel of 220 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of ten applications. Following a two week rest period, each of the 205 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 12/205 (5.8%) of the subjects exhibited sensitisation responses following the 10% challenge. Based on these results the test substance was determined to cause a low incidence of sensitisation characterized by mild to moderate reactions at 10%.
In another key study the dermal sensitisation of an analogue of this Low TBN substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 13) was evaluated in a human repeat insult patch test (Alworth, Schwartz & Erianne, 1995a;Table30). Five panels consisting of a total of 159 subjects were identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 154 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 4/154 (2.6%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to cause a low incidence of sensitisation characterized by mild to moderate reactions.
In another key study the dermal sensitisation of an analogue of this low TBN substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 13) was evaluated in a human repeat insult patch test (Eisenberg,1994a;Table30). A panel of 223 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of ten applications. Following a two week rest period, each of the 199 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 12/199 (6.0%) of the subjects exhibited sensitisation responses following the 10% challenge. Based on these results the test substance was determined to cause a low incidence of sensitisation characterized by mild to moderate reactions at 10%.
In another key study the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 13) was evaluated in a human repeat insult patch test (Alworth, Schwartz & Erianne, 1995b;Table30). Four panels consisting of a total of 157 subjects were identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 140 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 4/140 (2.9%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to cause a low incidence of sensitisation characterized by mild to moderate reactions in all but one subject.
In another key study, the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 13) was evaluated in a human repeat insult patch test (Eisenberg,1994b;Table30). A panel of 227 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of ten applications. Following a two week rest period, each of the 199 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 12/199 (6.0%) of the subjects exhibited sensitisation responses following the 10% challenge. Based on these results the test substance was determined to cause a low incidence of sensitisation characterized by mild to moderate reactions at 10%
In another key study the dermal sensitisation of an analogue of this low TBN substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 85), was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994a;Table30). A panel of 53 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 48 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 3/48 (6.3%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to cause a low incidence of sensitisation characterized by mild to moderate reactions in all but one subject.
In another key study the dermal sensitisation of an analogue of this low TBN substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 82), was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994e;Table30). A panel of 60 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 56 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 0/56 (0.0%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to not cause a sensitisation response.
In another key study the dermal sensitisation of an analogue of this low TBN substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 100) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994f;Table30). A panel of 52 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 51 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 0/51 (0.0%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to not cause a sensitisation response.
In another key study the dermal sensitisation of an analogue of this low TBN substance substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 13) was evaluated in a human repeat insult patch test (DiFiglia, Shanahan & Erianne, 1993d). A panel of 53 subjects was identified for this test. In the induction phase a 1% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 48 subjects that completed the induction phase was topically challenged with a 1% concentration of the test substance in mineral oil. A total of 0/48 (0%) of the subjects exhibited sensitisation responses following the 1% challenge. Based on these results the test substance was determined not to induce irritation or sensitisation at 1%.
Table30. Calcium Sulfonate Human Repeat Insult Patch Tests (HRIPT) with a 10% Induction Phase Concentration
Substance
Challenge
%
Challenge Response
Sensitisation Response (%)
Conclusion
Study
EC 263-093-9 (TBN = 30)
10%
7/142 with mild to moderate erythema/oedema including mild to moderate papular reactions; 1/142 with moderate erythema at 24 hours and severe erythema at 72 hours
8/142 (5.6)
Sensitiser: low incidence with mild to moderate reactions in all but one of 8 subjects
Alworth, Schwartz & Erianne, 1995c
EC 263-093-9 (TBN = 30)
10%
3/205 with mild erythema at original & virgin sites; 1/205 with moderate erythema at both areas; 7/205 with mild erythema original site; 1/205 with mild erythema virgin site
12/205 (5.8)
Sensitiser: low incidence with mild to moderate reactions
Eisenberg., 1994c
EC 616-278-7 (TBN = 13)
10%
2/154 with mild to moderate erythema with moderate papular reactions; 2/154 with mild to marked erythema and with moderate oedema and moderate papular reactions in the induction phase that were considered sensitised and, therefore were not challenged
4/154 (2.6)
Sensitiser: low incidence with mild to moderate reactions
Alworth, Schwartz & Erianne, 1995a
EC 616-278-7 (TBN = 13)
10%
6/199 with mild erythema at original sites; 5/199 with moderate erythema original site; 1/199 with moderate erythema virgin site
12/199 (6.0)
Sensitiser: low incidence with mild to moderate reactions
Eisenberg,, 1994a
EC 939-141-6 (TBN = 13)
10%
3/140 with mild to moderate erythema with mild to moderate oedema and/or mild to severe papular reactions in some; 1/140 with moderate erythema with mild to severe papular reaction including an adverse reaction report of reaction spreading to back/neck at 96 hrs with erythema deminishing at 192 hours but papular reaction spreading to the eyes
4/140 (2.9)
Sensitiser: low incidence with mild to moderate reactions in all but one of 4 subjects
Alworth, Schwartz & Erianne, 1995b
EC 939-141-6 (TBN = 13)
10%
1/210 with mild erythema original and virgin site; 6/210 with BP to mild erythema original site; 5/210 moderate erythema original site; 1/210 with marked erythema original site; 1/210 with mild erythema virgin site; 1/210 with marked erythema original site
15/210
(7.1)
Sensitiser: low incidence with mild to moderate reactions
Eisenberg, 1994b
EC 616-278-7 (TBN = 85)
10%
2/48 with mild to moderate erythema and 1/48 with moderate oedema and papular that spread beyond contact site during induction were not challenged
3/48
(6.3)
Sensitiser: low incidence with mild to moderate reactions
Shanahan, & Erianne, 1994a
EC 263-093-9 (TBN = 82)
10%
56/56 no reaction
0/56
(0)
Not a sensitiser
Shanahan, & Erianne, 1994e
EC 263-093-9 (TBN = 100)
10%
51/51 no reaction
0/51
(0)
Not a sensitiser
Shanahan & Erianne, 1994f
EC 263-093-9 = Sulfonic acids, petroleum, calcium salts
EC 616-278-7 = Benzene, polypropene derivs., sulfonated, calcium salts
EC 939-141-6 = Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts
In accordance with EU CLP Regulation (EC) No. 1272/2008, classification of low TBN calcium sulfonates is required for sensitisation with a specific concentration limit of 10%.
High TBN Calcium Sulfonates
In another key study the dermal sensitisation ofa high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 375) was evaluated in guinea pigs (Kiplinger, 1992a;Table 31). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 25% concentration of the test substance. After approximately one week the animals were rechallenged with a 25% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 25% challenge and 25% rechallenge were 0/12 and 0/12, respectively, and the mean 24/48 hour Draize scores were 0.4/0.4 and 0.4/0.4, respectively. The mean 24/48 hour Draize scores for the naïve controls at 25% challenge and 25% rechallenge were 0.1/0.1 and 0.4/0.3, respectively. Based on these results the test substance was determined not to be a sensitiser.
Table31. Dermal Sensitisation Study (Modified Buehler Design) in Guinea Pigs with a 100% High TBN Calcium Sulfonate (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 375) Induction: Challenge Results (Kiplinger, 1992a)
Group
Concentration
Mean Draize Score
# Positive
Conclusion
24 hours
48 hours
Test
25%
0.4
0.4
0/12
Not a sensitiser
Control
25%
0.1
0.1
Test
25%
0.4
0.4
0/12
Not a sensitiser
Control
25%
0.4
0.3
In another key study the dermal sensitisation ofa high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 400) was evaluated in guinea pigs (Reagan, 1988). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 60% concentration of the test substance. After approximately one week the animals were rechallenged with a 60% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 60% challenge and 60% rechallenge were 4/10 and 0/10, respectively, and the mean 26/48 hour Draize score severity indices were 0.7/0.5 and 0.0/0.2, respectively. The mean 26/48 hour Draize score severity indices for the naïve controls at 60% challenge and 60% rechallenge were 0.5/0.3 and 0.0/0.0, respectively. Based on these results the test substance was determined not to be a sensitiser.
In another key study the dermal sensitisation ofa high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 375) was evaluated in guinea pigs (Kiplinger, 1992b). The animals were treated topically with a 30% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 25% concentration of the test substance. After approximately one week the animals were rechallenged with a 25% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 25% challenge and 25% rechallenge was 0/12 and 0/11, respectively, and the mean 24/48 hour Draize scores were 0.4/0.3 and 0.4/0.3, respectively. The mean 24/48 hour Draize scores for the naïve controls at 25% challenge and 25% rechallenge were 0.5/0.4 and 0.2/0.2, respectively. Based on these results the test substance was determined not to be a sensitiser.
In another key study the dermal sensitisation ofa high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 300) was evaluated in guinea pigs (Blaszcak, 1992). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 25% concentration of the test substance. After approximately one week the animals were rechallenged with a 25% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 25% challenge and 25% rechallenge were 1/20 and 7/20, respectively, and the mean 24/48 hour Draize scores were 0.0/0.2 and 0.4/0.4, respectively. In the naïve controls 0/10 and 4/10 animals, respectively, exhibited positive irritation responses; the mean 24/48 hour Draize scores for the naïve controls at 25% challenge and 25% rechallenge were 0.0/0.0 and 0.5/0.4, respectively. Dermal responses to the corn oil vehicle alone were similar to the treated animals and naïve control. Based on these results the test substance was determined not to be a sensitiser.
In another key study the dermal sensitisation ofa high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 300) was evaluated in guinea pigs (Kiplinger, 1992c). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 25% concentration of the test substance. After approximately one week the animals were rechallenged with a 25% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 25% challenge and 25% rechallenge were 4/12 and 5/12, respectively, and the mean 24/48 hour Draize scores were 0.7/0.6 and 0.6/0.5, respectively. The mean 24/48 hour Draize scores for the naïve controls at 25% challenge and 25% rechallenge were 0.3/0.4 and 0.3/0.5, respectively. Based on these results the test substance was determined to be a sensitiser.
In another key study the dermal sensitisation of a high TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 300) was evaluated in guinea pigs (Bonnette, 1993a). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 50% concentration of the test substance. After approximately one week the animals were rechallenged with a 25% concentration of the test substance. Following the first rechallenge, the animals then were rechallenged with a 10% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 50%, 25%, and 10% were 8/10, 10/10, and 7/10, respectively, and the mean 24/48 hour Draize scores were 1.1/2.1, 1.6/1.7, and 1.2/1.2, respectively. The mean 24/48 hour Draize scores for the naïve controls at 50%, 25%, and 10% were 0.5/0.5, 0.7/0.8, and 0.3/0.5, respectively. Based on these results the test substance was determined to be a sensitiser.
In another key study the dermal sensitisation of a high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 300) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994d;Table32). A panel of 213 subjects was identified for this test. In the induction phase a 100% concentration of the test substance was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 200 subjects that completed the induction phase was topically challenged with a 100% concentration of the test substance. A total of 0/200 (0%) of the subjects exhibited sensitisation responses following the 100% challenge. Based on these results the test substance was determined not to induce irritation or sensitisation at 100%.
In another key study the dermal sensitisation of a high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 300) was evaluated in a human repeat insult patch test (DiFiglia, Shanahan & Erianne, 1993c,Table32). A panel of 53 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 51 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 0/51 (0%) of the subjects exhibited sensitisation responses following the 10% challenge. Based on these results the test substance was determined not to induce irritation or sensitisation at 10%.
In another key study the dermal sensitisation of an analogue ofa high TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 300) was evaluated in a human repeat insult patch test (DiFiglia, Shanahan & Erianne, 1993d,Table32). A panel of 53 subjects was identified for this test. In the induction phase a 1% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 50 subjects that completed the induction phase was topically challenged with a 1% concentration of the test substance in mineral oil. A total of 0/50 (0%) of the subjects exhibited sensitisation responses following the 1% challenge. Based on these results the test substance was determined not to induce irritation or sensitisation at 1%.
Table32. Human Repeat Insult Patch Tests (HRIPT) with a High TBN Sulfonic acids, petroleum, calcium salts; EC 263-093-9; TBN = 300): Challenge Results
Test Phase
Concentration
#Positive Responses
Conclusion
Study
24 hours
72 hours
Induction
100%
Not a sensitiser
Shanahan & Erianne, 1994d
Challenge
100%
0/200
0/200
Induction
10%
Not a sensitiser
DiFiglia, Shanahan & Erianne, 1993c
Challenge
10%
0/51
0/51
Induction
1%
Not a sensitiser
DiFiglia, Shanahan & Erianne, 1993d
Challenge
1%
0/50
0/50
In another key study the dermal sensitisation of a high TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 300) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1993b;Table33). Five panels consisting of a total of 241 subjects were identified for this test. In the induction phase a 100% concentration of the test substance was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 222 subjects that completed the induction phase was topically challenged with a 100% concentration of the test substance in mineral oil. The test substance did not induce any clinically significant irritation contact dermatitis. Only 1/222 (0.0%) of the subjects exhibited a reaction which was of questionable substance-related clinical significance. Based on these results the test substance was determined to not cause sensitisation.
In another key study the dermal sensitisation of a high TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 300) was evaluated in a human repeat insult patch test (Wachs, 1993;Table33). A panel of 57 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of ten applications. Following a two week rest period, each of the 51 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 0/51 (0.0%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to not cause a sensitisation response.
In another key study the dermal sensitisation of a high TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 300) was evaluated in a human repeat insult patch test (DiFiglia, Shanahan & Erianne, 1993a;Table33). A panel of 53 subjects was identified for this test. In the induction phase a 1% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 49 subjects that completed the induction phase was topically challenged with a 1% concentration of the test substance in mineral oil. A total of 0/49 (0.0%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to not cause a sensitisation response.
In another key study the dermal sensitisation of a high TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; EC 616-278-7; TBN = 300) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994b;Table33). A panel of 53 subjects was identified for this test. In the induction phase a 1% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 49 subjects that completed the induction phase was topically challenged with a 1% concentration of the test substance in mineral oil. A total of 0/49 (0.0%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to not cause a sensitisation response.
Table33. Human Repeat Insult Patch Tests (HRIPT) with a High TBN Calcium Sulfonate (Benzene, Polypropene Derivs., Sulfonated, Calcium Salts; EC 616-278-7; TBN = 300): Challenge Results
Test Phase
Concentration
#Positive Responses
Conclusion
Study
24 hours
72 hours
Induction
100%
Not a sensitiser
Shanahan & Erianne, 1993b
Challenge
100%
1/222
1/222
Induction
10%
Not a sensitiser
Wachs, 1993
Challenge
10%
0/51
0/511
Induction
1%
Not a sensitiser
DiFiglia, Shanahan & Erianne, 1993a
Challenge
1%
0/49
0/49
Induction
1%
Not a sensitiser
Shanahan & Erianne, 1994b
Challenge
1%
0/49
0/49
148 hours
In accordance with EU CLP Regulation (EC) No. 1272/2008, classification is not required for high TBN calcium sulfonates (TBN ≥ 300).
Conclusion
The weight-of-evidence indicates that low TBN calcium sulfonates (TBN < 300) are skin sensitisers with a specific concentration limit (SCL) of 10% and that high TBN calcium sulfonates (TBN ≥ 300) are not skin sensitisers. Studies in guinea pigs and human volunteers show that low TBN Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts; (EC 939-141-6; TBN = 13) are skin sensitisers. Numerous well-conducted, reliable, controlled human (HRIPT) studies with benzene, polypropene derivs., sulfonated, calcium salts (EC 616-278-7; TBN values ranging from 13 to 85), sulfonic acids, petroleum, calcium salts (EC 263-093-9; TBN = 30 to 100), and benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and benzenesulfonic acid, 4-octadecyl, calcium salts (EC 939-141-6; TBN = 13) show that low TBN calcium sulfonates do not cause sensitisation in a substantial number of subjects at 10% and lower. High TBN calcium sulfonates, sulfonic acids, petroleum, calcium salts (EC 263-093-9; TBN = 375 and 400) do not cause skin sensitisation in guinea pigs. Results of guinea pigs studies at TBN = 300 are mixed; two studies of sulfonic acids, petroleum, calcium salts, (EC 263-093-9) report no skin sensitisation while one study of sulfonic acids, petroleum, calcium salts (EC 263-093-9) and one study of benzene, polypropene derivs., sulfonated, calcium salts (EC 616-278-7) report skin sensitisation, However, numerous well-conducted, reliable, controlled human (HRIPT) studies with benzene, polypropene derivs., sulfonated, calcium salts (EC 616-278-7; TBN = 300) and sulfonic acids, petroleum, calcium salts (EC 263-093-9; TBN = 300), also show that high TBN (TBN ≥ 300) do not cause skin sensitisation. In accordance with EU CLP Regulation (EC) No. 1272/2008, classification is required for low TBN calcium sulfonates (TBN < 300) with a specific concentration limit of 10% and classification is not required for high TBN calcium sulfonates (TBN ≥ 300).References
Alworth KA, Schwartz H & Erianne JA (1995a). Clinical Safety Evaluation OS #18504G @ 10% in Mineral Oil Repeat Insult Patch Test, ETC Entry Nos. 3849.01, 4357.01, 4403.01, Panel Nos. 93081, 95009, 95016, 95032, 95037, 95052, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Alworth KA, Schwartz H & Erianne JA (1995b). Clinical Safety Evaluation OS # 87926C (same as OS #87926A) @ 10% in Mineral Oil Repeat Insult Patch Test, ETC Entry Nos. 3848.01, 4357.03, 4403.03, Panel Nos. 93080, 95022, 95045, 95070, 95074, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Alworth KA, Schwartz H & Erianne JA (1995c). Clinical Safety Evaluation OS # 65271E @ 10% in Mineral Oil Repeat Insult Patch Test, ETC Entry Nos. 3838.01, 4357.02, 4403.02, Panel Nos. 93072, 95018, 95025, 95062, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Ball N, Cagen S, Carrillo J-C, Certa H, Eigler D, Emter D, Emter R, Faulhammer F, Garcia C, Graham C, Haux C, Kolle SN, Kreiling R, Natsch A & Mehling A (2011). Evaluating the Sensitization Potential of Surfactants: Integrating Data from the Local Lymph Node Assay, Guinea Pig Maximization Test, and in vitro Methods in a Weight-of-Evidence Approach. Regulatory Toxicology & Pharmacology 60:389-400.
Basketter DA & Kimber I (2011). Skin Irritation, False Positives and the Local Lymph Node Assay: A guideline issue? Regulatory Toxicology & Pharmacology 61(1):137-140.
Blaszcak DL (1992). Closed-patch Repeated Insult Dermal Sensitization Study of OS# 18163Q in Guinea Pigs (Buehler Method), Bio/dynamics Project No.: 6153-91, Bio/dynamics Inc., East Millstone,New Jersey USA.
Bonnette KL (1993a). Dermal Sensitization Study in Guinea Pigs with OS# 65271E -Modified Buehler Design- (EPA-TSCA, EPA-FIFRA, OECD), SLS Study No. 3263.9, Springborn Laboratories, Inc., Spencerville, Ohio USA.
Bonnette KL (1993b). Dermal Sensitization Study in Guinea Pigs with OS# 67708C -Modified Buehler Design- (EPA-TSCA, EPA-FIFRA, OECD), SLS Study No. 3263.10, Springborn Laboratories, Inc., Spencerville, Ohio USA.
DiFiglia CJ, Shanahan RW & Erianne JA (1993a). Clinical Safety Evaluation OS #16928AJ (@ 10% in Mineral Oil) Repeated Insult Patch Test, ETC Entry No. 3864.01, Panel No. 93089, Essex Testing Clinic, Inc., Verona, New Jersey USA.
DiFiglia CJ, Shanahan RW & Erianne JA (1993b). Clinical Safety Evaluation OS #67708E Repeat Insult Patch Test, ETC Entry No. 3775.01, Panel No. 93027, Essex Testing Clinic, Inc., Verona, New Jersey USA.
DiFiglia CJ, Shanahan RW & Erianne JA (1993c). Clinical Safety Evaluation OS #16928AJ (1% in Mineral Oil) Repeat Insult Patch Test, ETC Entry No. 3825.02, Panel No. 93067, Essex Testing Clinic, Inc., Verona, New Jersey USA.
DiFiglia CJ, Shanahan RW & Erianne JA (1993d). Clinical Safety Evaluation OS #65271E (1% in Mineral Oil) Repeat Insult Patch Test, ETC Entry No. 3811.01, Panel No. 93059, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Eisenberg RR (1994a). Repeat Insult Patch Test 10% w/OS# 18504G In Squibb White Mineral Oil, Experiment Reference No. C94-0115, Consumer Product Testing Co., Fairfield, New Jersey USA.
Eisenberg RR (1994b). Repeat Insult Patch Test 10% w/OS# 87926A In Squibb White Mineral Oil, Experiment Reference No. C94-0116, Consumer Product Testing Co., Fairfield, New Jersey USA.
Eisenberg RR (1994c). Repeat Insult Patch Test 10% w/OS# 65271E In Squibb White Mineral Oil, Experiment Reference No. C94-0117, Consumer Product Testing Co., Fairfield, New Jersey USA.
Kiplinger GR (1992a). Skin Sensitization Study in Albino Guinea Pigs with OS 47860E, WIL Project Number: WIL-168017, WIL Reasearch Laboratories, Inc., Ashland, Ohio USA.
Kiplinger GR (1992b). Skin Sensitization Study in Albino Guinea Pigs with OS 47860E, WIL Project Number: WIL-168018, WIL Reasearch Laboratories, Inc., Ashland, Ohio USA.
Kiplinger GR (1992c). Skin Sensitization Study in Albino Guinea Pigs with OS 22969Q, WIL Project Number: WIL-168019, WIL Reasearch Laboratories, Inc., Ashland, Ohio USA.
Lees D (1996). OS65271G: Local Lymph Node Assay. Report No. CTL/E/132, Central Toxicology Laboratory, Alderley Park Macclesfield, Cheshire UK.
Reagan EL (1988). Dermal Sensitization Study of OS 68022 in Guinea Pigs, FDRL Study No. 9592C, Food & Drug Research Laboratories, Waverly, New York USA.
Shults SK (1993). Dermal Sensitization Study (Closed-Patch Repeated Insult) in Guinea Pigs with OS# 65271E. Document Number: 5577-92-0514-TX-001, Ricerca, Inc., 7528 Auburn Road, Painesville, Ohio USA.
Shanahan RW & Erianne JA (1993a). Clinical Safety Evaluation OS #65271E (100%) Repeat Insult Patch Test (Semi-Occulsive) Patch Test, ETC Entry No. 3900.02, Panel No. 93109, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Shanahan RW & Erianne JA (1993b). Clinical Safety Evaluation OS #67708E (@ 100%) Repeat Insult Patch Test Patch Test, ETC Entry No. 3870.01, Panel No. 93092, 93123, 93133, 93140, 93147, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Shanahan RW & Erianne JA (1994a). Clinical Safety Evaluation OS #65271E @ 20% in Mineral Oil Repeat Insult Patch Test Patch Test, ETC Entry No. 3999.01, Panel No. 93162, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Shanahan RW & Erianne JA (1994b). Clinical Safety Evaluation OS #13463M (@ 10% in Mineral Oil) Repeat Insult Patch Test Patch Test, ETC Entry No. 4044.01, Panel No. 94009, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Shanahan RW & Erianne JA (1994c). Clinical Safety Evaluation OS #17759W “Repeat Insult Patch Tests of Varius Sulfonates and Gear Oil Additive Test Articles, ETC Entry No. 4103.02, Panel Nos. 94069, 94071, 94081, 94084, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Shanahan RW & Erianne JA (1994d). Clinical Safety Evaluation OS #65841A Repeat Insult Patch Test, ETC Entry No. 4103.01, Panel Nos. 94068, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Shanahan RW & Erianne JA (1994e). Clinical Safety Evaluation OS #67708E @ 1% in Mineral Oil Repeat Insult Patch Test, ETC Entry No. 3834.01, Panel No. 93071, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Shanahan RW & Erianne JA (1994f). Clinical Safety Evaluation OS #16928AJ Repeat Insult Patch Test, ETC Entry No. 3911.01, Panels Nos. 93117, 93150, 93152, 93157, Essex Testing Clinic, Inc., Verona, New Jersey USA.
Migrated from Short description of key information:
The sensitisation potential of the substance has been assessed to humans and guinea pigs On the basis of these data the substance is considered sensitising, but the data available on human vounteers suggests that there is a clear threshold at 10%w/w, above which the substance is sensitising whilst at and below which the substance is not sensitising to humans.
Respiratory sensitisation
Endpoint conclusion
- Additional information:
As determined by ECHA guidance in Appendix R. 8 -11, and considering that no data from use of the substance are available, it is not possible to assess respiratory sensitisation or estimate a threshold or DNEL. It is known, nonetheless, that some, but not all, skin sensitisers can also cause respiratory sensitisation.
Migrated from Short description of key information:
Respiratory sensitisation has not been assessed. There are currently no validated in vitro or in vivo data and no data available from human exposure (e.g. workers) to demonstrate or deny respiratory senitisation.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)